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Background: Folate-nanoliposomes delivery system has emerged recently as a specific and safety delivery method
and gradually used as the carrier of a variety kinds of drugs including compounds, plasmids and siRNAs.
Methods: In this study, we established a bone marrow and bone metastasis xenograft mouse model by injecting
the LA-N-5 cell into the bone marrow cavity. Fluorescence microscopy, TUNEL Assay, Quantitative RT-PCR and
western blot were conducted to analysis the distribution of folate-nanoliposomes entrapped MYCN (V-myc
myelocytomatosis viral related oncogene) siRNA in mice and the relevant suppression effect.
Results: The folate-nanoliposomes entrapped MYCN siRNA can be specifically distributed in tumor tissues. Further
study shows that folate-nanoliposomes entrapped MYCN siRNA lead to MYCN mRNA expression significantly
down-regulated (>50%, and p < 0.05) compared with negative control siRNA treatment. MYCN protein expression
was inhibited about 60% in vivo, thus induced tumor cell apoptosis markedly.
Conclusion: This study point to a new way for treatment of metastatic neuroblastoma and could widen the
application of folate-nanoliposomes delivery system in tumor therapy.
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Neuroblastoma is the most common extracranial solid
tumor occurring in children, which accounts for about
15% of all childhood cancer deaths [1,2]. It is generally
accepted that the amplification of the MYCN proto-
oncogene is highly relevant to the genesis and prognosis
of neuroblastoma [3,4]. MYCN is an important member
of the myc family that includes 3 strong oncogenes,
MYC, MYCN, and MYCL [5]. Targeting MYCN gene
has developed into a promising therapeutic strategy
[6-8]. Small interference RNA (siRNA) is synthetic short
double-stranded RNA, which can induce the destruction
of homologous mRNA when introduced into a cell [9].
siRNA has been developed into an effective tool for sup-
pressing target proteins expression by specifically digesting
their mRNAs [10]. siRNAs have been widely investigated* Correspondence: suoqin@yahoo.com
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reproduction in any medium, provided the oras therapeutic agents to treat a wide range of human dis-
eases including neuroblastoma [7,11].
Folate, a nontoxic low-weigh compound, is vital for
tumor cell proliferation and survival. Studies show that
tumor cells can express 200-folds more folate receptor
on the membrane than normal cells, which is accord-
ance to the high intake of folate in tumor cells. Folate
receptor is overexpressed in a wide range of human can-
cer cells, including ovarian cancer, endometrial cancer,
head and neck cancers, myeloid leukaemia, and some
pediatric cancers [12]. Folate conjugating on liposomes
with entrapped drugs [13-16] or plasmids [17-20] has
been used successfully to deliver drugs to folate-receptor
-expressing cancer cells. Our previous study had re-
vealed that the folate receptor was highly expressed on
the membrane of LA-N-5 neuroblastoma cells. In this
study, we want to further investigate whether folate
receptor-targeted liposome can act as a good delivery
tool of MYCN siRNA and exert a satisfying therapeutic
effect on neuroblastoma.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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metastasis xenograft mouse model by injecting the LA-
N-5 cell into the bone marrow cavity. Then we exam-
ined whether folate-nanoliposomes entrapped MYCN
siRNA can specifically distribute to tumor tissues and
suppress MYCN gene expression as well as induce apop-
tosis in neuroblastoma cells.
Materials and methods
Animals
BALB/c nude mice (4 wk) were used for all experiments.
All animals were housed in the Experimental Animal
Centre of PLA General Hospital, and all procedures
were approved by the Institutional Animal Care and Use
Committee of PLA General Hospital.
Cell culture
LA-N-5 neuroblastoma cell was the generous gift of Dr.
Robert Seeger from Children’s Hospital Los Angeles, and
the cells were grown in RPMI 1640 medium (GIBCO
BRL, USA) containing 15% fetal bovine serum (Hyclone,
USA), 2 mmol/L l-glutamine, 100 IU/ml penicillin G
and 100 μg/mL streptomycin (all were from Huamei
Company, China) in a humidified 5% CO2 and 95% air
atmosphere at 37°C.
Establishment of the bone marrow and bone metastasis
xenograft mouse model
Previously described procedure was introduced in the
current study [21,22]. Briefly, LA-N-5 neuroblastoma
cells were harvested and washed by centrifugation and
resuspended in cold serum-free medium prior to injec-
tion. Mice were immobilized in a restraining device, and
cells (105 cells in 5 μl) were injected into the bone mar-
row cavity of the femoral proximal metaphysis. About
five weeks later, the diameters of tumors can be up to
5 mm and the bone metastasis model is successfully
established.
Preparation of the folate-nanoliposome entrapped MYCN
siRNA
The folate-nanoliposome entrapped MYCN siRNA with
Cy-3 fluorescence tag was the generous gift from Dr.
Robert J. Lee (Ohio State University, College of Phar-
macy). siRNA sequences were as follows: MYCN siRNA
sense: 5′-CGGAGAUGCUGCUUGAGAA dtdt-3′, anti-
sense: 5′-UUCUCAAGCAGCAUCUCCG dtdt-3′; the
negative control siRNA: sense: 5′-UUCUCCGAACGU
GUACGU dtdt-3′, anti-sense: 5′-ACGUGACAC GUU
CGGAGAA dtdt-3′.
siRNA distribution analysis and gene therapy
For siRNA distribution analysis, LA-N-5 neuroblastoma
cells were injected into mice bone marrow cavity toestablish the bone marrow and bone metastasis xeno-
graft models. Then the folate-nanoliposome entrapped
MYCN siRNA with Cy3 tag (3 mg/kg) was injected into
mice via lateral tail vein, and mice were sacrificed 8 hours
after injection. Tumors of femur and other indicated or-
gans (heart, lung, liver, kidney) were harvested, embed-
ded in optimum cutting temperature compound (OCT)
and sectioned into 4 μm frozen sections. Tissues sec-
tions were observed under fluorescence microscopy
(stimulating wavelength, 554 nm). Three views of each
organ were chosen randomly and subjected to calculate
the average integrated optical density (IOD) with Image
pro plus 6.0 Software. In the gene therapy experiment,
mice were divided into two groups (6 mice for each
group). LA-N-5 neuroblastoma cells were injected into
mice bone marrow cavity to establish the bone marrow
and bone metastasis xenograft model. Then the folate-
nanoliposome entrapped MYCN siRNA with Cy3 tag
(3 mg/kg/d) were injected into one group of mice by lat-
eral tail vein. The other group of mice were injected
with folate-nanoliposome entrapped the control siRNA
(3 mg/kg/d). Mice were sacrificed at the sixth day after 5
injections of folate-nanoliposome entrapped siRNAs.
Tumors frozen sections were analyzed by TUNEL Assay.
Quantitative RT-PCR analysis
The cells were harvested and RNA was extracted by
using the Ultrapure RNA Kit (CWbio.Co.Ltd). Briefly,
cells were lysed in RLT buffer and RNA was purified
according to the manufacturer’s instructions. RNase-free
DNase set (CWbio.Co.Ltd) was used to remove any con-
taminating genomic DNA. The cDNA was synthesized
using HiFi-MMLV cDNA Kit (CWbio.Co.Ltd). The pri-
mer sequences for MYCN were: 5′-CTCAGTACCTCC
GGAGAG-3′ (sense) and 5′-GGCATCGTIGAGGATC-
3′ (antisense). The primer sequences for GAPDH
were:5′-TGCACCACCAACTGCTTAGC-3′ (sense) and
5′-GGCATGGACTGTGGTCATGAG-3′ (antisense). Real-
time PCR was performed on an Roche LightCycler
480IIsystem, using LightCycler 480 SYBR GreenIMaster
(Roche). Each sample was determined in triplicate. MYCN
mRNA expression was calculated as MYCN copies/GAPDH
copies. Relative standard curve method was used to deter-
mine the relative mRNA expression of MYCN gene.
Western blot
Tumor frozen samples from each mouse in a same
group were mixed and total protein was extracted. Pro-
teins were separated by a precast 4-12% SDS-PAGE gel
(Sigma) and electrophoretically transferred to a PVDF
membrane, followed by incubation with anti-β-actin
antibody (1/2000 ab3280 Abcam, Cambridge, MA, USA)
and anti-n-Myc antibody [NCM II 100] (1:1000 ab16898
Abcam, Cambridge, MA, USA). Protein bands were
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Buchinghamshire, UK) and visualized by autoradiography.TUNEL assay
Briefly, frozen tumor samples were cut on a cryostat and
got 4 μm-thick sections. Slices were fixed with acetone
and soaked in 3% hydrogen peroxide-methanol solution
for 20 min, then rinsed in PBS for 3 times. Fixed sec-
tions were incubated with proteinase K (20 μg/ml) for
20 min at 37°C and washed withTBS for 3 times. Then they
were incubated with TdT buffer containing digoxigenin
labelled desoxyuridinetriphosphate (DIG-UTP) and dATP
for 2 h at 37°C, and immersed in stop solution for
30 min at room temperature. After washing, the sections
were incubated with strept avidin-biotin-peroxidase
complex (SABC) antibody solution for 60 min at 37°C,
followed by incubation with DAB for 20 min. Slices were
counterstained with hematoxylin and examined with a
fluorescence microscope.Statistical analysis
All experiments were performed at least in triplicate and
data are expressed as means ± SEM. Statistical differ-
ences were analyzed by two-tailed t test. P < 0.05 was
considered statistically significant.Figure 1 A diagram of target delivery of MYCN siRNA by folate-nanolResults
Folate-nanoliposome entrapped MYCN siRNA is
specifically distributed in tumor tissues
LA-N-5 neuroblastoma cells were injected into mice
bone marrow cavity to establish the bone marrow and
bone metastasis xenograft model. Then mice were
injected with the folate-nanoliposome entrapped MYCN
siRNA with Cy3 tag (Figure 1) by tail vein, and sacrificed
8 hours after injection. Tissues sections were observed
under fluorescence microscopy and showed that Cy3 fluor-
escence was very bright in tumors in bones (Figure 2A, B).
Liver, kidney, heart and lung tissues have weak or no
visible fluorescence (Figure 2A, B). This indicates that
folate-nanoliposome entrapped MYCN siRNA is speci-
fically distributed in tumor tissues.
In vivo gene silencing effect of folate-nanoliposome
entrapped MYCN siRNA in LA-N-5 neuroblastoma
Mice were injected (i.v.) with folate-nanoliposome en-
trapped MYCN siRNA or control siRNA for 5 days and
gene silencing effect of MYCN siRNA in LA-N-5 neuro-
blastoma were examined by real-time PCR and Western
blot. As shown in Figure 3A, MYCN mRNA expression was
significant down-regulated (>50%) by folate-nanoliposome
entrapped MYCN siRNA compared to negative control
siRNA treatment (p < 0.01). Western blot result showed
MYCN protein expression was about 60% inhibited byiposomes.
Figure 2 Distribution of folate-nanoliposome entrapped MYCN siRNA: A, Cy3 fluorescence of different tissues. a, tumors tissue; b, heart;
c, lung; d, liver; e, kidney. This graph is one representative result of three views; B, Quantitative analysis of fluorescence intensity of each tissue.
Fluorescence intensity was expressed as integrated optical density (IOD). Results are expressed as means ± SE.
Figure 3 The in vivo gene silencing effect of folate-nanoliposome entrapped MYCN siRNA in LA-N-5 neuroblastoma: A, Quantitative
RT-PCR analysis of MYCN gene expression. Results are normalized to GAPDH expression and are presented as fold increases over the control.
6 mice each group, *P < 0.05, **P < 0.01; B, Western blot analysis of MYCN gene expression. Frozen tumor samples of each mouse in a same
group were mixed and analyzed by Western blot. The right graph is a quantitative analysis of the left one.
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Figure 4 TUNEL assay of LA-N-5 neuroblastoma: A, folate-nanoliposome entrapped control siRNA group; B, folate-nanoliposome
entrapped MYCN siRNA group.
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These data demonstrate that systematic injection of folate-
nanoliposome entrapped MYCN siRNA can silence MYCN
gene expression of tumor tissues efficiently.
The pro-apoptotic effect of folate-nanoliposome
entrapped MYCN siRNA in neuroblastoma
Gene therapeutic effect of folate-nanoliposome en-
trapped MYCN siRNA was evaluated by TUNEL assay
of neuroblastoma. As shown in Figure 4, MYCN siRNA
treatment group caused much more TUNEL positive
cells than control siRNA treatment group. This indicates
that folate-nanoliposome entrapped MYCN siRNA treat-
ment can lead to apoptosis of neuroblastoma in vivo.
Discussion
Our results showed MYCN knockdown induces apop-
tosis of metastatic neuroblastoma in vivo, MYCN gene,
located on the short arm of chromosome 2, is only
expressed during the stages of embryonic development
of the nervous system, kidney, lung and spleen [23].
MYCN gene is considered a proto-oncogene associated
with the malignant tumors growth [24-26]. Since MYCN
gene amplification plays a key role in the neuroblastoma
progression, inhibition the MYCN gene expression be-
comes a probable strategy for high-risk neuroblastoma
therapy. Studies by other groups [27-29] have demon-
strated that inhibition of MYCN gene expression in
neuroblastoma cells makes cell cycle arrest at G1 phase,
and promotes tumor cell apoptosis or differentiation
into neural cells. The MYCN gene is a promising drug
target for treating peripheral and central nervous system
tumors [30].
Although the therapeutic strategy targeting MYCN
in vivo by siRNA is attractive, the traditional drugs deliv-
ery methods seem to be nonspecific and toxic [31]. The
folate receptor-targeted liposome delivery system has
emerged recently as a specific and safety delivery method
and become the frontier of drugs delivery. This study
was designed to examine the specificity and efficacy
of folate-nanoliposome entrapped MYCN siRNA intreatment of metastatic neuroblastoma, showing that
MYCN siRNA was distributed specically in tumor tis-
sues under the direction of folate-folate receptor inter-
action and further silences MYCN gene expression both
in mRNA and protein levels and finally induces apop-
tosis of neuroblastoma cells. This indicates that folate-
nanoliposome entrapped MYCN siRNA could be used
in future gene therapy of neuroblastoma. Of note, the
in vivo gene knockdown efficiency is up to 60% in pro-
tein level, which is much higher than that of traditional
methods such as lipofection or calcium-phosphate
transfection [31].
This study points to a new way for treatment of meta-
static neuroblastoma and widen the application of
folate-nanoliposomes delivery system in tumor therapy.
The high specificity, efficiency and safety make folate
receptor-targeted liposome delivery system a killer mace
in siRNAs-mediated cancer gene therapy.
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